Advanz Agrees Multi-Market Omalizumab Deal With Alvotech

Gains Rights To Market Xolair Biosimilar In Europe, Canada And Australiasia

 
• By Dave Wallace

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Blue lungs with world map
Advanz has gained international rights to the asthma treatment • Source: Shutterstock

More from Deals

More from Business